Skip to main content
Premium Trial:

Request an Annual Quote

Quantum-Si Q2 Net Loss Down 9 Percent

NEW YORK – Quantum-Si on Tuesday reported a net loss of $32.4 million in the second quarter of 2022, down 9 percent from $35.7 million in the year-ago period.

The proteomics startup did not post any revenues during the quarter ended June 30.

During a conference call following release of the financial results, Jonathan Rothberg, the company's founder and interim CEO, said it remained on track to launch its Platinum proteomic platform this year.

Quantum-SI's loss per share during the quarter was $.23 versus a loss per share of $.97 in Q2 2021. The weighted-average shares used to compute net loss per share in Q2 2021 was 139.0 million versus 36.9 million in Q2 2021.

Quantum-Si's R&D spending was up 41 percent during the quarter to $18.5 million from $13.1 million in Q2 2021. Its SG&A spending was $11.7 million, down 39 percent from $19.1 million in Q2 2021.

As of June 30, the company had $81.3 million in cash and cash equivalents and $319.4 million in marketable securities.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.